50 years since the discovery of bromocriptine

被引:20
作者
Besser, G. Michael [1 ]
Pfeiffer, Ronald F. [2 ]
Thorner, Michael O. [3 ]
机构
[1] St Bartholomews Hosp, Med, London, England
[2] Oregon Hlth & Sci Univ, Neurol, Portland, OR 97201 USA
[3] Univ Virginia, Med, Charlottesville, VA 22904 USA
关键词
LONG-TERM TREATMENT; PROLACTIN SECRETION; PARKINSONS-DISEASE; GROWTH-HORMONE; L-DOPA; PLASMA; PROGESTERONE; INHIBITION; GALACTORRHEA; RECEPTORS;
D O I
10.1530/EJE-18-0378
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ergotism is the long-term ergot poisoning by ingestion of rye or other grains infected with the fungus Claviceps purpurea and more recently by excessive intake of ergot drugs. It has either neuropsychiatric or vascular manifestations. In the Middle Ages, the gangrenous poisoning was known as St. Anthony's fire, after the order of the Monks of St. Anthony who were particularly skilled at treating the condition. In 1917, Prof. Arthur Stoll returned home to Switzerland from Germany, to lead the development of a new pharmaceutical department at Sandoz Chemical Company. Stoll, using the special methods of extraction learned from his work with his mentor Willstetter, started his industrial research work with ergot. He succeeded in isolating, from the ergot of rye, ergotamine as an active principle of an old popular remedy for excessive post-partum bleeding. The success of this discovery occurred in 1918 and was translated into a pharmaceutical product in 1921 under the trade name Gynergen. In subsequent work, Stoll and his team were leaders in identifying the structure of the many other alkaloids and amines produced by Claviceps purpurea. This was the cultural background and scientific foundation on which bromocriptine was discovered.
引用
收藏
页码:R69 / R75
页数:7
相关论文
共 46 条
[1]   CLINICAL AND PATHOLOGICAL EFFECTS OF BROMOCRIPTINE ON PROLACTIN-SECRETING AND OTHER PITUITARY-TUMORS [J].
BARROW, DL ;
TINDALL, GT ;
KOVACS, K ;
THORNER, MO ;
HORVATH, E ;
HOFFMAN, JC .
JOURNAL OF NEUROSURGERY, 1984, 60 (01) :1-7
[2]   GALACTORRHEA - SUCCESSFUL TREATMENT WITH REDUCTION OF PLASMA PROLACTIN LEVELS BY BROM-ERGOCRYPTINE [J].
BESSER, GM ;
MCNEILLY, AS ;
EDWARDS, CRW ;
PARKE, L ;
FORSYTH, IA .
BRITISH MEDICAL JOURNAL, 1972, 3 (5828) :669-&
[3]  
BRUNDELR.R, 1973, OBSTET GYNECOL, V41, P884
[4]   BROMOCRIPTINE IN PARKINSONISM [J].
CALNE, DB ;
TEYCHENNE, PF ;
CLAVERIA, LE ;
EASTMAN, R ;
GREENACRE, JK ;
PETRIE, A .
BMJ-BRITISH MEDICAL JOURNAL, 1974, 4 (5942) :442-444
[5]   DEVELOPMENTS IN TREATMENT OF PARKINSONISM [J].
CALNE, DB .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (25) :1433-1434
[6]   EFFECT OF ERGOT DRUGS ON CENTRAL CATECHOLAMINE NEURONS - EVIDENCE FOR A STIMULATION OF CENTRAL DOPAMINE NEURONS [J].
CORRODI, H ;
FUXE, K ;
HOKFELT, T ;
LIDBRINK, P ;
UNGERSTEDT, U .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 (05) :409-412
[7]   AROMATIC AMINO ACIDS AND MODIFICATION OF PARKINSONISM [J].
COTZIAS, GC ;
VANWOERT, MH ;
SCHIFFER, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (07) :374-&
[8]   SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE [J].
COTZIAS, GC ;
PAPAVASILIOU, PS ;
FEHLING, C ;
KAUFMAN, B ;
MENA, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1970, 282 (01) :31-+
[9]   Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes [J].
DeFronzo, Ralph A. .
DIABETES CARE, 2011, 34 (04) :789-794
[10]  
DELPOZO E, 1972, J CLIN ENDOCR METAB, V35, P768, DOI 10.1210/jcem-35-5-768